Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin ®, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 14 th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, at 11:30 a.m. EST. The conference will be held at the Waldorf=Astoria Hotel in New York, NY. A live and archived webcast of the company presentation can be accessed via the Investor Relations section of the Company’s website at www.opexatherapeutics.com. About Opexa Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS). The Company’s lead therapy, Tovaxin ®, a personalized cellular immunotherapy treatment, is in late stage clinical development targeting both Secondary Progressive and Relapsing Remitting MS. Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time. For more information, please visit the Company’s website at www.opexatherapeutics.com.